.png){kind=icon}
.png){kind=icon}
Return
Severe cutaneous adverse reactions
.png){kind=icon}
PRE
AI
DOI：10.1038/s41572-024-00514-0.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Severe cutaneous adverse reactions (SCARs), which include Stevens-Johnson syndrome and toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (also known as drug-induced hypersensitivity syndrome), acute generalized exanthematous pustulosis, and generalized bullous fixed drug eruption, are life-threatening conditions. The pathogenesis of SCARs involves T cell receptors recognizing drug antigens presented by human leukocyte antigens, triggering the activation of distinct T cell subsets. These cells interact with keratinocytes and various immune cells, orchestrating cutaneous lesions and systemic manifestations. Genetic predisposition, impaired drug metabolism, viral reactivation or infections, and heterologous immunity influence SCAR development and clinical presentation. Specific genetic associations with distinct SCAR phenotypes have been identified, leading to the implementation of genetic screening before prescription in various countries to prevent SCARs. Whilst systemic corticosteroids and conventional immunomodulators have been the primary therapeutic agents, evolving strategies, including biologics and small molecules targeting tumour necrosis factor, different cytokines, or Janus kinase signalling pathways, signify a shift towards a precision management paradigm that considers individual clinical presentations. Severe cutaneous adverse reactions (SCARs) are a group of adverse reactions characterized by severe skin eruptions and varying degrees of systemic involvement. In this Primer, Hung et al. summarize current knowledge of epidemiology and mechanisms of SCARs and discuss diagnosis, treatment and quality of life of patients. They also highlight outstanding research questions.
Keywords:
STEVENS-JOHNSON-SYNDROME
TOXIC EPIDERMAL NECROLYSIS
GENERALIZED EXANTHEMATOUS PUSTULOSIS
QUALITY-OF-LIFE
FIXED DRUG ERUPTION
HYPERSENSITIVITY SYNDROME/DRUG REACTION
SYSTEMIC SYMPTOMS DRESS
SYNDROME (DIHS)/DRUG REACTION
IMMUNE CHECKPOINT INHIBITORS
T-CELLS
Journal
N
IF:
60.6
Papers:
644
Citations:
3.8W
View more organizations